CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.

Also called NCT04369664

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 151 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04369664
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04369664. Non-randomized; no masking; primary purpose treatment. Start 2020-08-12 (actual); primary completion 2023-09-25 (actual). Results posted on 2024-10-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CHOlesterol Lowering and Residual Risk in Type 2 Diabetes
Acronym
CHORD
Intervention (Drug)
Statin
Intervention (Drug)
PCSK9 inhibitor
Intervention (Drug)
Ezetimibe 10mg
Lead sponsor
NYU Langone Health (class: other)

Record details

Record id
cardio:ct-nct04369664
Content hash
5b581c1cc8aac8d38453dbcb2ac8d49b93cfb102ca0fed49611be748422001f4